Docetaxel for malignant mesothelioma: Phase II study of the Eastern Cooperative Oncology Group

Clinical Lung Cancer

Volumn 6, Issue 1, 2004, Pages 43-47

  Belani, Chandra P ^a,b   Adak, Sudeshna ^a   Aisner, Seena ^a   Stella, Philip J ^a   Levitan, Nathan ^a   Johnson, David H ^a  

^a Eastern Cooperative Oncology Group   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Granulocytopenia; Leukopenia; Monotherapy; Pleurodesis

Indexed keywords

ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL;

ABDOMINAL CRAMP; ADULT; AGED; ANOREXIA; ARTICLE; BLEEDING; CANCER GROWTH; CANCER RECURRENCE; CANCER RESEARCH; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HUMAN; ILEUS; LEUKOPENIA; LIVER TOXICITY; LUNG CANCER; LUNG TOXICITY; MALE; MALIGNANT MESOTHELIOMA; METABOLIC DISORDER; MOTOR DYSFUNCTION; NAUSEA AND VOMITING; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; STOMATITIS; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT WITHDRAWAL;

EID: 4444330118     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2004.n.020     Document Type: Article

References (18)

1. Testa JR, Pass HI, Carbone M. Molecular Biology of Mesothelioma. In: De Vita V, Hellman S, Rosenberg S, et al, eds. Principles and Practice of Oncology (6th ed). Philadelphia, PA: Lippincott Williams and Wilkins, 2001:1937-1943.
2. Carbone M, Fisher S, Powers A, et al. New molecular and epidemiological issues in mesothelioma: Role of SV40. J Cell Physiol 1999; 180:167-172.
3. Butel JS, Lednicky JA. Cell and molecular biology of Simian virus 40: Implications for human infections and disease. J Natl Cancer Inst 1999; 91:119-133.
4. Bianchi AB, Mitsunaga SI, Cheng JQ et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci U S A 1995; 92:10854-10858.
5. Murthy SA, Testa JR. Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma. J Cell Physiol 1999; 180:150-157.
6. Frizelle SP, Grim J, Zhou J, et al. Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression. Oncogene 1998; 16:3087-3095.
7. Britton M. The epidemiology of mesothelioma. Sem Oncol 2002; 29:18-25.
8. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma. A review. J Clin Oncol 1996; 14:1007-1017.
9. Kindler HJ, Herndon JE, Vogelzang NJ, et al. CPT-11 in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 9733). Proc Am Soc Clin Oncol 2000; 19:578a (Abstract #1978).
10. Knuttila A, Ollikainen T, Halma M, et al. Docetaxel and irinotecan in the treatment of malignant pleural mesothelioma-a feasibility study. Anti-Cancer Drugs 2000;11:257-261.
11. Van Meerbeeck JP, Baas P, Debruyne C, et al. A phase II study of gemcitabine in patients with malignant pleural mesothelioma. Cancer 1999; 85:2577-2582.
12. Van Meerbeeck JP, Debruyne C, Van Zandwijk N, et al. Paclitaxel for malignant pleural mesothelioma: A phase II study of the EORTC Lung Cancer Cooperative Group. Br J Cancer 1996; 74:961-963.
13. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;15; 21:2636-2644.
14. Ollikaninen T, Knuuttila A, Suhonen S, et al. In vitro sensitivity of normal human mesothelial and malignant mesothelioma cell lines to four new chemotherapeutic agents. Anti-cancer Drugs 2000; 11:93-99.
15. Vorobiof DA, Rapoport BL, Chasen MR, et al. Malignant pleural mesothelioma: A phase Il trial with docetaxel. Ann Oncol 2002; 13:412-415.
16. Scagliotti G, Shin D, Kindler H, et al. Phase II study of Alimta (pemetrexed disodium, MTA) single agent in patients with malignant pleural mesothelioma. Eur J Cancer 2001; 37(suppl 6):20 (Abstract #66).
17. Thödtmann R, Depenbrock H, Dumez H, et al. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol 1999; 17:3009-3016.
18. Calvert AJ, Hughes AN, Calvert PM, et al. Alimta in combination with carboplatin demonstrates clinical activity against malignant mesothelioma in a phase I trial. Pro Am Soc Clin Oncol 2000; 19:495a (Abstract #1936).